Your browser doesn't support javascript.
loading
Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study.
Bekker, Charlotte L; Bossina, Sacha; de Vera, Mary A; Bartlett, Susan J; de Wit, Maarten; March, Lyn; Shea, Beverley; Evans, Vicki; Richards, Dawn; Tong, Allison; Tugwell, Peter; Tymms, Kathleen; Scholte-Voshaar, Marieke; Kelly, Ayano; van den Bemt, Bart J F.
Affiliation
  • Bekker CL; C.L. Bekker, PhD, Radboud University Medical Centre, Research Institute for Health Sciences, Nijmegen, the Netherlands; Charlotte.bekker@radboudumc.nl.
  • Bossina S; S. Bossina, MSc, Department of Rheumatology, Liverpool Hospital, Sydney, Australia.
  • de Vera MA; M.A. de Vera, Assistant Professor, PhD, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, and Arthritis Research Canada, Richmond, British Columbia, Canada.
  • Bartlett SJ; S.J. Bartlett, Professor, PhD, Department of Medicine, McGill University and Research Institute, McGill University Health Centres, Montreal, Québec, Canada, and Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • de Wit M; M. de Wit, PhD, OMERACT Patient Research Partner, the Netherlands.
  • March L; L. March, Professor, PhD, Institute of Bone and Joint Research, Kolling Institute of Medical Research, and Department of Rheumatology, Royal North Shore Hospital, and Northern Clinical School, The University of Sydney, Sydney, Australia.
  • Shea B; B. Shea, PhD, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Evans V; V. Evans, Adjunct Assistant Professor, PhD, BOptom, Faculty of Health, University of Canberra, Canberra, Australia.
  • Richards D; D. Richards, PhD, Five02 Labs Inc., and Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada.
  • Tong A; A. Tong, Professor, PhD, Centre for Kidney Research, The Children's Hospital at Westmead, and Sydney School of Public Health, The University of Sydney, Sydney, Australia.
  • Tugwell P; P. Tugwell, Professor, MD, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
  • Tymms K; K. Tymms, Associate Professor, MBBS, FRACP, College of Health and Medicine, Australian National University, and Department of Rheumatology, Canberra Hospital, Canberra, Australia.
  • Scholte-Voshaar M; M. Scholte-Voshaar, MSc, OMERACT Patient Research Partner, and University of Twente, Enschede, the Netherlands.
  • Kelly A; A. Kelly, Clinical Associate Lecturer, MBBS, FRACP, Department of Rheumatology, Liverpool Hospital, Sydney, Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, College of Health and Medicine, Australian National University, Canberra, and South Western Clinical School, UNSW Medic
  • van den Bemt BJF; B.J. van den Bemt, Professor, PharmD, Radboud University Medical Centre, Research Institute for Health Sciences, and Sint Maartenskliniek, Nijmegen, the Netherlands. The authors declare no conflicts of interest relevant to this article.
J Rheumatol ; 48(9): 1480-1487, 2021 09.
Article in En | MEDLINE | ID: mdl-33993113
ABSTRACT

OBJECTIVE:

To describe the perspectives of patients with inflammatory arthritis (IA) on outcome domains of trials evaluating medication adherence interventions.

METHODS:

Adult patients (≥ 18 yrs) with IA taking disease-modifying antirheumatic drugs from centers across Australia, Canada, and the Netherlands participated in 6 focus groups to discuss outcome domains that they consider important when participating in medication adherence trials. We analyzed the transcripts using inductive thematic analysis.

RESULTS:

Of the 38 participants, 23 (61%) had rheumatoid arthritis and 21 (55%) were female. The mean age was 57.3 ± (SD 15.0) years. Improved outcome domains that patients wanted from participating in an adherence trial were categorized into 5 types medication adherence, adherence-related factors (supporting adherence; e.g., medication knowledge), pathophysiology (e.g., physical functioning), life impact (e.g., ability to work), and economic impact (e.g., productivity loss). Three overarching themes reflecting why these outcome domains matter to patients were identified how taking medications could improve patients' emotional and physical fitness to maintain their social function; how improving knowledge and confidence in self-management increases patients' trust and motivation to take medications as agreed with minimal risk of harms; and how respect and reassurance, reflecting health care that values patients' opinions and is sensitive to patients' individual goals, could improve medication-taking behavior.

CONCLUSION:

Patients value various outcome domains related to their overall well-being, confidence in medication use, and patient-healthcare provider relationships to be evaluated in future adherence trials.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Medication Adherence Type of study: Prognostic_studies / Qualitative_research Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Rheumatol Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Medication Adherence Type of study: Prognostic_studies / Qualitative_research Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Rheumatol Year: 2021 Document type: Article